Transforming Healthcare with Artificial Intelligence: Global Insights

By Thanusha Pillay

July 8, 2024

Introduction

Artificial intelligence (AI) in healthcare holds immense potential to enhance patient outcomes, safety, and affordability of high-quality care. However, the journey to fully realise this is complex. This article published npj Digital Medicine explores the perspectives of the Future of Health (FOH) group, an international community of health leaders. These leaders highlight four key action areas to effectively channel AI’s capabilities.

Improving Data Quality to Power Artificial Intelligence

AI algorithms rely heavily on the accuracy and completeness of the data they process. High-quality data is essential for AI tools to function correctly and deliver reliable results. FOH members emphasise that identifying and ensuring the availability of high-priority data elements is vital. These elements include data with the most predictive value, high patient value, and importance for performance and bias analyses.

Policy incentives play a significant role in encouraging high-quality data collection. Aligned payment incentives for healthcare quality and safety, along with performance standards for data reliability, completeness, and timeliness, are essential. For example, the multinational project STANDING Together aims to improve data quality and representativeness of data for AI tools.

Building Trust and Verifying Artificial Intelligence Tools

Demonstrating that AI tools are both effective and safe within specific patient populations is paramount to building trust in AI. However, this is challenging as AI’s performance can vary significantly across different sites and over time due to changes in health data patterns and population characteristics.

Real-world evaluations are crucial for long-term predictions and preventing long-term complications. Health systems must prioritise implementing data standards and infrastructure that facilitate retraining or tuning of algorithms, test for performance and bias, and ensure scalability across the organisation. Meanwhile, efforts such as Health AI: The Global Agency for Responsible AI in Health and the Coalition for Health AI aim to build and certify validation mechanisms to ensure AI’s trustworthiness.

Sharing Data for Better Artificial Intelligence

High-quality internal data alone is insufficient to power and evaluate all AI applications. Effective AI-enabled predictive software for clinical care requires interoperable data across health systems to build a diverse picture of patient healthcare. FOH members recommend that healthcare leaders work with researchers and policymakers to connect detailed encounter data with longitudinal outcomes. This approach helps assure valid outcome evaluations and addresses potential confounding and population subgroup differences.

For example, the South African National Digital Health Strategy outlines interventions that improve adopting digital technologies while complying with the 2013 Protection of Personal Information Act. The country has made progress in building a Health Patient Registration System and releasing a Health Normative Standards Framework to improve data flow across institutional and geographic boundaries.

Incentivising Progress for Artificial Intelligence Impact

Financial incentives are necessary for accelerating the development, evaluation, and adoption of AI tools. There is a need for value-based payments, aligning financial incentives for high-quality data, effective AI tools, and improved patient outcomes and healthcare operations.

Value-based payments, which focus on quality, safety, better health, and lower costs for patients, are essential. These payments rely on high-quality, standardised, interoperable datasets from diverse sources. Within value-based payments, data are critical for measuring care quality and patient outcomes, adjusted for factors outside clinical control. This alignment of incentives promotes high-quality data collection and development of AI tools that genuinely benefit patients and healthcare systems.

Conclusion

Data has become the most valuable commodity in healthcare. The actions of healthcare leaders and policymakers in the coming years is the key to enhancing health outcomes, safety, affordability, and equity. By improving data quality, building trust, sharing data, and incentivising progress, the healthcare industry can truly take advantage of AI’s potential.

Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.